<DOC>
	<DOC>NCT00240253</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of adding Symlin to an established regimen of insulin glargine in subjects with type 2 diabetes who are not achieving glycemic targets.</brief_summary>
	<brief_title>A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Pramlintide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Islet Amyloid Polypeptide</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Has HbA1c &gt;7.0% and &lt;=10.5% Has a body mass index (BMI) &gt;=25 kg/m2 and &lt;=45 kg/m2 Has received insulin glargine for 3 months prior to study start and has been on a stable dose for 1 month prior to study start If taking oral antidiabetic agents, has been on a stable dose for at least 2 months Has been previously treated with Symlin/pramlintide (or has participated in a Symlin/pramlintide clinical study) Has received any investigational drug within 1 month of screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>Amylin</keyword>
	<keyword>Symlin</keyword>
	<keyword>pramlintide</keyword>
	<keyword>insulin glargine</keyword>
</DOC>